Robert Wasserman
Stock Analyst at Benchmark
(3.40)
# 916
Out of 5,182 analysts
119
Total ratings
50%
Success rate
3.62%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Upgrades: Buy | $95 | $85.35 | +11.31% | 13 | Feb 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $64.49 | +39.56% | 11 | Feb 19, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $175 → $220 | $241.79 | -9.01% | 12 | Nov 7, 2025 | |
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $63.79 | -13.78% | 7 | Nov 3, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $100 → $38 | $5.23 | +617.02% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $55.11 | +36.09% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $8.20 | +82.93% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.44 | +316.67% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $41.97 | -16.61% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $4.16 | - | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $21.41 | +40.12% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $3.23 | +54.80% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $8.03 | +49.44% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.65 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $118.29 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.62 | -13.42% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $100 | $2.99 | +3,250.08% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.27 | +3,203.96% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $180.62 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $468.04 | +23.92% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 20, 2026
Upgrades: Buy
Price Target: $95
Current: $85.35
Upside: +11.31%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Buy
Price Target: $75 → $90
Current: $64.49
Upside: +39.56%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $175 → $220
Current: $241.79
Upside: -9.01%
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $63.79
Upside: -13.78%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $100 → $38
Current: $5.23
Upside: +617.02%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $55.11
Upside: +36.09%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $8.20
Upside: +82.93%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.44
Upside: +316.67%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $41.97
Upside: -16.61%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.16
Upside: -
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $21.41
Upside: +40.12%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $3.23
Upside: +54.80%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.03
Upside: +49.44%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.65
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $118.29
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.62
Upside: -13.42%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $100
Current: $2.99
Upside: +3,250.08%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.27
Upside: +3,203.96%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $180.62
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $468.04
Upside: +23.92%